Management of ocular surface disorders needed for patients on dupilumab
Click Here to Manage Email Alerts
Management of ocular surface disorders may be needed for patients who are on dupilumab to treat atopic dermatitis, according to a presentation at the American Academy of Dermatology virtual meeting.
The retrospective chart review included patients who received at least 52 weeks of dupilumab treatment or discontinued before 52 weeks due to ocular surface disorders.
Conjunctivitis and conjunctivitis-related symptoms, including red eyes, dry eyes, discharge and blepharitis, were assessed.
“Conjunctivitis is an ongoing safety concern associated with dupilumab treatment for AD,” the study authors wrote.
Conjunctivitis or other ocular surface disorders were reported in 21 of 58 patients (36%), with 17 of 21 (81%) reporting symptoms in the first 16 weeks of dupilumab treatment.
Treatments for ocular surface disorders included corticosteroids, antihistamines/mast cell stabilizers, antibiotics, eye drops and others.
Only 11 cases (52%) experienced complete resolution of ocular surface disorders by week 52.
Three cases (14%) saw improvement, while five (24%) had ongoing symptoms. Two cases discontinued dupilumab treatment due to ocular adverse events, which were both attributed to inadequate management, according to the study.